Merck
  • Home
  • Search Results
  • Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up.

Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up.

Archives of disease in childhood. Fetal and neonatal edition (2007-09-13)
K J Rademaker, L S de Vries, C S P M Uiterwaal, F Groenendaal, D E Grobbee, F van Bel
ABSTRACT

The benefits versus the risks of postnatal administration of steroids in preterm-born infants are still debatable. This review examines the literature on postnatal hydrocortisone treatment for chronic lung disease (CLD) in preterm-born infants with a particular focus on the effects of such treatment on long-term neurodevelopmental outcomes. Quantitative published evidence does not point to a clear advantage of treatment with hydrocortisone over dexamethasone with regard to the impact on long-term neurological outcomes. However, in the absence of a randomised comparison, a consensus may soon have to be reached on the basis of the best available evidence whether hydrocortisone should replace dexamethasone in the treatment of CLD.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
氢化可的松, BioReagent, suitable for cell culture
Sigma-Aldrich
氢化可的松 溶液, 50 μM, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
氢化可的松, ≥98% (HPLC)
Sigma-Aldrich
氢化可的松, γ-irradiated, powder, BioXtra, suitable for cell culture
Supelco
氢化可的松, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
皮质醇标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
氢化可的松, European Pharmacopoeia (EP) Reference Standard
USP
氢化可的松, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
氢化可的松, meets USP testing specifications
峰鉴别用氢化可的松, European Pharmacopoeia (EP) Reference Standard
Supelco
氢化可的松, VETRANAL®, analytical standard